Derivative of anti-tumor protein endostatin and application

A technology of endostatin and its derivatives, which is applied in the direction of anti-tumor drugs, applications, peptide/protein components, etc., can solve the problems of instability, short half-life of endostatin, and affecting the effect of endostatin anti-tumor therapy, and achieve half-life Long-lasting, high anti-tumor biological activity

Active Publication Date: 2017-05-17
孙嘉琳 +1
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, in monkey experiments and human clinical trials, it was found that the half-life of endostatin was very short, showing exponential degradation, and the content of endostatin in the body decreased by a hundred times or even close to zero after 10 hours (Acta Pharmacol Sin, 26, 124-128, 2005 ; J Clin Oncol,20,3792-3803,2002), it is shown that it is very unstable in animals, which will greatly affect the antitumor therapeutic effect of endostatin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Derivative of anti-tumor protein endostatin and application
  • Derivative of anti-tumor protein endostatin and application
  • Derivative of anti-tumor protein endostatin and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 A derivative of the anti-tumor protein endostatin, including a fusion protein of endostatin linked to the constant region of antibody IgG, its anti-tumor activity and the half-life of the fusion protein in mice.

[0050] protein sample

[0051] Sample 1: pre-sequence-endostatin; the front of endostatin shown in SEQ ID NO.4 is connected with the pre-sequence shown in SEQ ID NO.2, and the signal peptide in the pre-sequence is to allow expressed endostatin can be secreted extracellularly.

[0052] Sample 2: fusion protein of pre-sequence-endostatin-antibody IgG partial constant region CH1 (shown in SEQ ID NO.8, the nucleic acid sequence encoding SEQ ID NO.8 is shown in SEQ ID NO.7).

[0053] Sample 3: pre-sequence-endostatin-antibody IgG partial constant region CH1CH2 fusion protein (shown in SEQ ID NO.10, the nucleic acid sequence encoding SEQ ID NO.10 is shown in SEQ ID NO.9).

[0054] Sample 4: pre-sequence-endostatin-antibody IgG constant region CH1CH2CH3 f...

Embodiment 2

[0061] Example 2 Evaluation of Endostatin Derivatives, Newly Introduced Arg in Front of the N-Terminus of Endostatin

[0062] The pre-sequence-endostatin-antibody IgG constant region fusion protein (SEQ ID NO.11 and SEQ ID NO.12) of Example 1 sample 4 was selected as the experimental material, and the amino acid sequence (SEQ ID NO.12) was used to determine Explain that 1-23 amino acids are derived from albumin, 1-18 is the signal peptide of albumin, 19-23 are the 5 amino acids at the N-terminal of mature albumin, of which there are two Arg, 24-206 are endostatin , 207-536 is the constant region of antibody IgG, which consists of CH1, CH2 and CH3. Various experimental proteins:

[0063] Sample 1: pre-sequence-endostatin-antibody IgG constant region fusion protein, shown by SEQ ID NO.12, wherein 19-23 are Arg-Gly-Val-Phe-Arg.

[0064] Sample 2: pre-sequence-endostatin-antibody IgG constant region fusion protein point mutant 1, in which 19-23 is Ala-Gly-Val-Phe-Arg, the agg po...

Embodiment 3

[0071] Example 3 Examination of the effect of glycosylation sites on the activity of endostatin fusion proteins

[0072] Using the pre-sequence-endostatin-antibody IgG constant region CH1CH2CH3 fusion protein (SEQ ID NO.11 and SEQ ID NO.12) of Example 1 as the experimental material to construct derivatives, that is, in front of the N-terminus of endostatin Or add a glycosylated amino acid short peptide Gly-Ala-Ser-Asn-Ser-Thr-Gly-Ala-Ser after the C-terminus, where Asn-Ser-Thr is the position of glycosylation, and the sugar chain is connected to Asn . The plasmid (pHEK293Ultra) expressing the front sequence-endostatin-antibody IgG constant region CH1CH2CH3 fusion protein (shown in SEQ ID NO.12, encoding the nucleic acid sequence SEQ ID NO.11 of SEQ ID NO.12) in Example 1 was selected Expression Vector II) for various gene manipulations, and the gene fragments of these mutants can also be directly synthesized, and then inserted into the plasmid (pHEK293 Ultra Expression Vector...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a derivative of anti-tumor protein endostatin. An amino acid sequence of the endostatin is as shown in SEQ. ID. NO4. The derivative is characterized in that the endostatin is connected with a constant region of an antibody IgG, or Arg is introduced to the front of an N end of the endostatin, or amino acid oligopeptide of a glycosylation site is introduced to the front of the N end, the back of a C end, or the front of the N end and the back of the C end of the endostatin, or one Arg of Arg62 and Arg63 in the amino acid sequence of the endostatin generates point mutation, or one Arg of Arg128 and Arg129 generates point mutation, or one Arg of the Arg128 and the Arg129 generates point mutation while one Arg of the Arg62 and the Arg63 generates point mutation. The derivative of the anti-tumor protein endostatin is stable in vivo, long in half-life period and high in anti-tumor bioactivity.

Description

technical field [0001] The invention relates to a derivative of anti-tumor protein endostatin and its application, belonging to the field of biomedical anti-tumor drugs. Background technique [0002] Tumor growth depends on the formation of blood vessels, and the formation of blood vessels is regulated by angiogenesis factors and inhibitors. Inhibiting the growth of tumor blood vessels is an effective way to treat tumors. Endostatin (Endostatin) has the function of inhibiting angiogenesis, so it has been paid attention to in the anti-angiogenesis treatment of tumors. Endostatin is a C-terminal 184 amino acid fragment produced by the hydrolysis of collagen XVIII. It can effectively inhibit a variety of different types of tumors. Its biological effects are broad-spectrum and have no drug resistance. It is the best discovered so far. Angiogenesis inhibitors (Exp Cell Res, 312, 594-607, 2006). [0003] However, in monkey experiments and human clinical trials, it was found that...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C07K14/78C12N15/62C12N15/12A61K38/39A61K47/68A61K48/00A61P35/00
Inventor 孙嘉琳
Owner 孙嘉琳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap